Can a new biologic calm the immune attack in ulcerative colitis?

NCT ID NCT07747480

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a drug called aletekitug is safe and tolerable for people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The drug works by blocking a protein called IL-18, which may play a role in the inflammation that damages the gut. The study will give the drug to about 16 participants who have not previously used advanced therapies, and will closely monitor them for side effects and changes in lab results, vital signs, and heart activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alekitug (anti-IL-18), a biologic drug
What this could lead to: If successful, this could lead to a new treatment option for ulcerative colitis, potentially helping to control the disease and improve symptoms.
What could go wrong: This is an early-phase trial with only 16 participants, so results may not apply to everyone. The drug may cause side effects or may not be effective enough to warrant further study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system disorder inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE

More trials for these conditions

Other studies related to the condition(s) this trial covers.